BR0017374A - Tratamento de disfunção sexual usando antagonista de bombesina - Google Patents

Tratamento de disfunção sexual usando antagonista de bombesina

Info

Publication number
BR0017374A
BR0017374A BR0017374-6A BR0017374A BR0017374A BR 0017374 A BR0017374 A BR 0017374A BR 0017374 A BR0017374 A BR 0017374A BR 0017374 A BR0017374 A BR 0017374A
Authority
BR
Brazil
Prior art keywords
treatment
sexual dysfunction
bombesin antagonist
bombesin
antagonist
Prior art date
Application number
BR0017374-6A
Other languages
English (en)
Inventor
Maria Isabel Gonzalez
Michael Higginbottom
Robert Denham Pinnock
Martyn Clive Pritchard
Herman Thijs Stock
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0017374A publication Critical patent/BR0017374A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"TRATAMENTO DE DISFUNçãO SEXUAL USANDO ANTAGONISTA DE BOMBESINA". A presente invenção refere-se a antagonistas de receptor de bombesina foram verificados ser úteis no tratamento de disfunção sexual em ambos machos e fêmeas.
BR0017374-6A 2000-11-17 2000-11-17 Tratamento de disfunção sexual usando antagonista de bombesina BR0017374A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2000/004380 WO2002040022A1 (en) 2000-11-17 2000-11-17 Treatment of sexual dysfunction using bombesin antagonist

Publications (1)

Publication Number Publication Date
BR0017374A true BR0017374A (pt) 2003-09-30

Family

ID=9886325

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0017374-6A BR0017374A (pt) 2000-11-17 2000-11-17 Tratamento de disfunção sexual usando antagonista de bombesina

Country Status (13)

Country Link
EP (1) EP1333829A1 (pt)
JP (1) JP2004525864A (pt)
KR (1) KR20040062416A (pt)
CN (1) CN1479618A (pt)
AU (1) AU2001214046A1 (pt)
BR (1) BR0017374A (pt)
CA (1) CA2426521A1 (pt)
HU (1) HUP0303500A2 (pt)
IL (1) IL155814A0 (pt)
MX (1) MXPA03003481A (pt)
PL (1) PL366002A1 (pt)
WO (1) WO2002040022A1 (pt)
ZA (1) ZA200303250B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10123163A1 (de) 2001-05-09 2003-01-16 Gruenenthal Gmbh Substituierte Cyclohexan-1,4-diaminderivate
US7244743B2 (en) 2002-06-05 2007-07-17 Solvay Pharmaceuticals Gmbh Non-peptidic BRS-3 agonists
CN117665174B (zh) * 2024-02-01 2024-04-23 巴中市产品质量检验检测中心 一种检测pde5和ssri的方法及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369094A (en) * 1990-11-29 1994-11-29 The Administrators Of The Tulane Educational Fund Polypeptide bombesin antagonists
US5650395A (en) * 1995-03-13 1997-07-22 Hurel; Steven Treatment of pulmonary hypertension
US6194437B1 (en) * 1996-08-22 2001-02-27 Warner-Lambert Company Non-peptide bombesin receptor antagonists
AU2180600A (en) * 1998-12-18 2000-07-12 Warner-Lambert Company Non-peptide nk1 receptors antagonists
WO2000067708A2 (en) * 1999-05-07 2000-11-16 Board Of Regents, The University Of Texas System Oral steroidal hormone compositions and methods of use
EP1057829B1 (en) * 1999-06-04 2002-11-20 The Jordanian Pharmaceutical Manufacturing and Medical Equipment Co.Ltd. Novel compounds and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
CN1479618A (zh) 2004-03-03
AU2001214046A1 (en) 2002-05-27
HUP0303500A2 (hu) 2004-01-28
EP1333829A1 (en) 2003-08-13
PL366002A1 (en) 2005-01-24
MXPA03003481A (es) 2004-09-10
IL155814A0 (en) 2003-12-23
ZA200303250B (en) 2004-04-26
JP2004525864A (ja) 2004-08-26
WO2002040022A1 (en) 2002-05-23
CA2426521A1 (en) 2002-05-23
KR20040062416A (ko) 2004-07-07

Similar Documents

Publication Publication Date Title
ATE303804T1 (de) Behandlung von sexueller funktionsstörung mit bombesin rezeptor antagonisten
PT1135153E (pt) Utilizacoes para antagonistas e agonistas de receptores eph para tratar desordens vasculares
HK1055721A1 (en) Compounds to treat alzheimer&#39;s disease.
LU92854I2 (fr) Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu&#39;un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil
WO1999047131A3 (en) Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
EP1762236A3 (en) Formulations of alpha adrenergic receptor antagonists and their uses
HK1039900B (zh) 一種α1B型腎上腺體的選擇性抑制劑的改善性功能障礙的用途
BG105534A (en) 5ht1 means and method for the treatment of migraine
IL141235A0 (en) Combined use of an alpha-adrenoceptor antagonist and amuscarinic antagonist in the treatment of benign prostatic hyperplasi
NO963064L (no) Behandling av normotensive glaukoma med angiotensin-II-antagonister
EA200401584A1 (ru) Способ содействия прекращению курения
SG149872A1 (en) Antagonists of the bradykinin b1 receptor
CY1105257T1 (el) Χρηση των ανταγωνιστων των υποδοχεων της αγγειοτενσινης ii στην θepαπεια του οξεος εμφραγματος του μυοκαρδιου
MXPA03009185A (es) Antagonistas de receptor a2a de adenosina combinados con compuestos de actividad neurotrofica en el tratamiento de la enfermedad de parkinson.
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
AU2001285318A1 (en) Use of an aldosterone receptor antagonist to improve cognitive function
DE69911023D1 (de) Antagonisten des gonadotropin freisetzenden hormons
GEP20074132B (en) Use of adenosine receptor a1 antagonists for treatment of pulmonary disease
BR0109002A (pt) Receptores antagonistas il-8
BR0017374A (pt) Tratamento de disfunção sexual usando antagonista de bombesina
EE200200337A (et) Uued ühendid ning nende kasutamine
ATE557007T1 (de) Arylpyrimidine geeignet zur behandlung von sexualhormonbedingten zuständen wie endometriose, prostatakrebs und dergleichen
GB9805559D0 (en) A combination of therapeutic agents
BR0115364A (pt) Tratamento de disfunção sexual
MX9603199A (es) Antagonistas de receptores a endotelina.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFENTE AO DESPACHO 8.6 DA RPI 2012 DE 28/07/2009.